Biogen
BIIB
$194.38
+6.00%
Biogen Inc. is an established biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative and rare diseases, operating within the Drug Manufacturers - General industry. The company is a legacy leader in the multiple sclerosis market but is actively transitioning its identity towards a broader neuroscience and rare disease player through its newer franchises. The current investor narrative is dominated by its strategic acquisition of Apellis Pharmaceuticals, which adds two fast-growing drugs to its portfolio, and recent positive regulatory catalysts, including FDA approval for a high-dose version of its spinal muscular atrophy drug Spinraza, as the market assesses the company's ability to offset declines in its core MS business with new growth drivers.…
BIIB
Biogen
$194.38
Related headlines
BIIB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $252.69 and implied upside of +30.0% versus the current price.
Average Target
$252.69
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$156 - $253
Analyst target range
Analyst coverage is limited, with only 8 analysts providing estimates, indicating this is a stock with significant but focused institutional interest. The consensus sentiment appears mixed, as evidenced by recent institutional ratings which include actions like 'Reduce' from HSBC and 'Neutral' from Citigroup and Wedbush, balanced against 'Buy' or 'Outperform' ratings from firms like Canaccord Genuity and RBC Capital; however, a specific consensus recommendation and average target price are not available in the provided data, preventing a calculation of implied upside. The range of analyst estimates shows high uncertainty, with estimated EPS for the coming period spanning from $19.18 to $22.31, and estimated revenue from $10.09 billion to $11.33 billion; this wide dispersion reflects the fundamental debate around the success of Biogen's new growth initiatives and the integration of the Apellis acquisition, with the high targets banking on successful execution and the low targets likely pricing in continued core franchise erosion.
Bulls vs Bears: BIIB Investment Factors
The evidence presents a balanced but tense investment case. The bull side is supported by a fortress balance sheet, a compelling forward valuation discount, and concrete pipeline catalysts that directly target the company's core challenge. The bear case is grounded in persistent revenue declines, extreme earnings volatility, and significant market skepticism as evidenced by high short interest. Currently, the bull side holds a slight edge due to the quantifiable valuation support (11.52x forward P/E) and the tangible nature of recent growth additions. The single most important tension in the investment debate is whether the revenue growth from new franchises (Spinraza high-dose, Apellis drugs) can accelerate fast enough to not just stabilize, but actually reverse the -7.15% YoY top-line decline before investor patience wears thin.
Bullish
- Strong Balance Sheet & Cash Flow: Biogen maintains a robust financial position with a current ratio of 2.68 and a moderate debt-to-equity of 0.38. The company generated $2.14 billion in TTM free cash flow, providing significant liquidity to fund strategic acquisitions like Apellis without over-leveraging.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.52x, a significant discount to its trailing P/E of 19.96x. This implies the market expects a substantial earnings recovery, likely driven by contributions from new growth franchises and the Apellis acquisition.
- Positive Pipeline & Regulatory Catalysts: Recent FDA approval for a high-dose version of Spinraza and the strategic acquisition of Apellis's fast-growing drugs provide concrete near-term growth drivers. These events directly address the need to offset declines in the legacy MS business.
- Sustained Long-Term Uptrend: The stock has gained 54.28% over the past year and is trading near the upper end of its 52-week range ($115.25-$202.41). This strong technical momentum suggests a positive shift in market sentiment regarding the company's transition.
Bearish
- Persistent Revenue Decline: Q4 2025 revenue of $2.279 billion declined -7.15% YoY, following a volatile pattern from a Q2 2025 peak of $2.645 billion. This underscores the ongoing pressure from the declining MS franchise, which still contributed 40% of 2025 revenue.
- Extreme Earnings Volatility: Profitability is highly inconsistent, with the latest quarter showing a net loss of -$48.4 million, a stark reversal from the prior quarter's net income of $466.5 million. This quarterly volatility complicates forecasting and increases investment risk.
- High Short Interest: A short ratio of 3.96 indicates significant skepticism among some investors. This elevated short interest reflects the bearish view that the company's growth initiatives may fail to fully offset core business erosion.
- Recent Momentum Divergence: Despite a strong 1-year gain, the stock is down -2.54% over the past month, underperforming the SPY's +8.7% gain. This short-term weakness suggests the rally may be overextended and facing consolidation near technical resistance at $202.41.
BIIB Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 54.28% one-year price change. As of the latest close at $184.38, the stock is trading at approximately 85% of its 52-week range ($115.25 to $202.41), positioning it near the upper bounds of its yearly range, which suggests strong momentum but also raises questions about potential overextension. Recent momentum shows a divergence, with a 7.45% gain over the past three months contrasting with a -2.54% decline over the past month, indicating a short-term consolidation or pullback within the longer-term uptrend, potentially a healthy pause after the significant rally. Key technical support is at the 52-week low of $115.25, while immediate resistance is at the 52-week high of $202.41; a decisive breakout above $202.41 would signal a resumption of the bullish trend, while a breakdown below the recent lows near $172 would suggest a deeper correction. The stock's beta of 0.162 indicates it has been significantly less volatile than the broader market (SPY), which is unusual for a biopharma stock and may reflect its status as a large, mature company amidst a transformative phase.
Beta
0.16
0.16x market volatility
Max Drawdown
-20.4%
Largest decline past year
52-Week Range
$115-$202
Price range past year
Annual Return
+61.8%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | +3.6% | +12.6% |
| 3m | +10.3% | +2.5% |
| 6m | +26.0% | +4.3% |
| 1y | +61.8% | +28.4% |
| ytd | +9.3% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Revenue growth is inconsistent and currently negative, with the most recent quarterly revenue of $2.279 billion representing a -7.15% year-over-year decline; this follows a volatile multi-quarter pattern where revenue peaked at $2.645 billion in Q2 2025 before falling, indicating persistent top-line pressure primarily from the declining MS franchise, which contributed 40% of 2025 revenue. Profitability is highly variable, with the latest quarter showing a net loss of -$48.4 million and a gross margin of 78.23%; this contrasts sharply with the prior quarter's net income of $466.5 million and a gross margin of 64.29%, highlighting significant quarterly volatility in earnings, though the trailing twelve-month net margin stands at 13.18%. The balance sheet is robust with a strong current ratio of 2.68 and a moderate debt-to-equity ratio of 0.38, while the company generates substantial cash, with free cash flow over the trailing twelve months at $2.139 billion, providing ample liquidity to fund growth initiatives like the Apellis acquisition without over-leveraging the balance sheet.
Quarterly Revenue
$2.3B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.78%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
Given the company's positive trailing net margin of 13.18%, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 19.96x, while the forward PE is significantly lower at 11.52x, indicating the market expects a substantial recovery in earnings over the next twelve months, likely factoring in contributions from new products and acquisitions. Compared to industry averages, Biogen's trailing PE of 19.96x is not directly comparable without a provided sector average, but its Price-to-Sales (PS) ratio of 2.63x and EV/EBITDA of 9.60x suggest a valuation that balances its legacy cash flows against its growth transition story. Historically, the stock's current trailing PE of 19.96x is below its own historical range seen in recent years, where it has frequently traded above 20x and even into the 30s, suggesting the current valuation may not be demanding relative to its own history if the company successfully executes its growth strategy.
PE
20.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -137x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on Biogen's inconsistent earnings and declining core business. The company's most recent quarterly revenue declined -7.15% YoY, and earnings swung from a $466.5 million profit in Q3 to a -$48.4 million loss in Q4, highlighting extreme volatility. While the balance sheet is strong, the company remains heavily reliant on its MS franchise (40% of 2025 revenue), which is in structural decline, creating a persistent growth gap that new products must fill. The success of the Apellis acquisition is critical, as failure to integrate it successfully would pressure the balance sheet used to fund it without delivering the promised growth.
Market & Competitive Risks include valuation compression if growth expectations are not met. The stock trades at 85% of its 52-week high, suggesting limited near-term upside without flawless execution. The wide dispersion in analyst EPS estimates ($19.18 to $22.31) reflects high uncertainty, increasing the risk of negative earnings surprises. Furthermore, the neuroscience and rare disease space is intensely competitive, with constant pressure from new therapies that could erode the commercial potential of Biogen's newer drugs like Leqembi and Skyclarys. The stock's low beta of 0.162 may not hold if the growth transition falters, potentially leading to de-rating.
Worst-Case Scenario involves a failure of new growth drivers to gain traction coinciding with an accelerated decline in the MS and CD20 collaboration revenues. This could trigger multiple compression, driving the stock back toward its 52-week low of $115.25. Combined with potential integration missteps from the Apellis deal, this could lead to sustained earnings misses and analyst downgrades. In this adverse scenario, an investor could face a drawdown of approximately -37% from the current price of $184.38 to the 52-week low, aligning with the stock's recent maximum drawdown of -20.4% observed within the provided price data.